JP2006508193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508193A5 JP2006508193A5 JP2005510377A JP2005510377A JP2006508193A5 JP 2006508193 A5 JP2006508193 A5 JP 2006508193A5 JP 2005510377 A JP2005510377 A JP 2005510377A JP 2005510377 A JP2005510377 A JP 2005510377A JP 2006508193 A5 JP2006508193 A5 JP 2006508193A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sialidase
- binding
- seq
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 89
- 108010006232 Neuraminidase Proteins 0.000 claims 60
- 102000005348 Neuraminidase Human genes 0.000 claims 60
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 150000001413 amino acids Chemical group 0.000 claims 12
- 230000001580 bacterial effect Effects 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 210000002919 epithelial cell Anatomy 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 9
- 102000004190 Enzymes Human genes 0.000 claims 8
- 108090000790 Enzymes Proteins 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 241000186044 Actinomyces viscosus Species 0.000 claims 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 6
- 244000052769 pathogen Species 0.000 claims 6
- 230000001717 pathogenic effect Effects 0.000 claims 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- 229920002971 Heparan sulfate Polymers 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 241000186046 Actinomyces Species 0.000 claims 4
- 241000193468 Clostridium perfringens Species 0.000 claims 4
- 101000583741 Clostridium perfringens Sialidase Proteins 0.000 claims 4
- 102100028755 Sialidase-2 Human genes 0.000 claims 4
- 241000607626 Vibrio cholerae Species 0.000 claims 4
- 239000006199 nebulizer Substances 0.000 claims 4
- 239000002674 ointment Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
- 101001123851 Homo sapiens Sialidase-2 Proteins 0.000 claims 3
- 101000601384 Homo sapiens Sialidase-4 Proteins 0.000 claims 3
- 241000187708 Micromonospora Species 0.000 claims 3
- 241000187750 Micromonospora viridifaciens Species 0.000 claims 3
- 101000583743 Micromonospora viridifaciens Sialidase Proteins 0.000 claims 3
- 210000002889 endothelial cell Anatomy 0.000 claims 3
- 229960002897 heparin Drugs 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- 108010083590 Apoproteins Proteins 0.000 claims 2
- 102000006410 Apoproteins Human genes 0.000 claims 2
- 108010039627 Aprotinin Proteins 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 101000757319 Homo sapiens Antithrombin-III Proteins 0.000 claims 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims 2
- 101001123859 Homo sapiens Sialidase-1 Proteins 0.000 claims 2
- 101001123847 Homo sapiens Sialidase-3 Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 102100028760 Sialidase-1 Human genes 0.000 claims 2
- 102100028756 Sialidase-3 Human genes 0.000 claims 2
- 102100037729 Sialidase-4 Human genes 0.000 claims 2
- 108010067390 Viral Proteins Proteins 0.000 claims 2
- 210000001552 airway epithelial cell Anatomy 0.000 claims 2
- 229960004405 aprotinin Drugs 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 102000052624 human CXCL8 Human genes 0.000 claims 2
- 102000052834 human SERPINC1 Human genes 0.000 claims 2
- 229960004336 human antithrombin iii Drugs 0.000 claims 2
- -1 inhalant Substances 0.000 claims 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007937 lozenge Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 235000019833 protease Nutrition 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- 241000321096 Adenoides Species 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 claims 1
- 101100516397 Homo sapiens NEU4 gene Proteins 0.000 claims 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 241000712431 Influenza A virus Species 0.000 claims 1
- 241000713196 Influenza B virus Species 0.000 claims 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 101150084651 Neu2 gene Proteins 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 108091093037 Peptide nucleic acid Chemical class 0.000 claims 1
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 1
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 1
- 210000002534 adenoid Anatomy 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 229940038704 clostridium perfringens Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 102000043494 human AREG Human genes 0.000 claims 1
- 102000052196 human PF4 Human genes 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 108010052968 leupeptin Proteins 0.000 claims 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229940118696 vibrio cholerae Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42853502P | 2002-11-22 | 2002-11-22 | |
| US60/428,535 | 2002-11-22 | ||
| US46421703P | 2003-04-19 | 2003-04-19 | |
| US60/464,217 | 2003-04-19 | ||
| PCT/US2003/037158 WO2004047735A2 (en) | 2002-11-22 | 2003-11-21 | Broad spectrum anti-viral therapeutics and prophylaxis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508193A JP2006508193A (ja) | 2006-03-09 |
| JP2006508193A5 true JP2006508193A5 (enExample) | 2008-09-11 |
| JP5348651B2 JP5348651B2 (ja) | 2013-11-20 |
Family
ID=32397132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005510377A Expired - Fee Related JP5348651B2 (ja) | 2002-11-22 | 2003-11-21 | 広域抗ウイルス治療および予防薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8084036B2 (enExample) |
| EP (1) | EP1567185B1 (enExample) |
| JP (1) | JP5348651B2 (enExample) |
| KR (2) | KR20050085130A (enExample) |
| CN (2) | CN101804200A (enExample) |
| AU (1) | AU2003294401C1 (enExample) |
| CA (1) | CA2506526C (enExample) |
| WO (1) | WO2004047735A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8084036B2 (en) * | 2002-11-22 | 2011-12-27 | Nexbio, Inc. | Broad spectrum anti-viral therapeutics and prophylaxis |
| US7807174B2 (en) * | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| US8512710B2 (en) * | 2002-11-22 | 2013-08-20 | Ansun Biopharma, Inc. | Class of therapeutic protein based molecules |
| WO2007070875A1 (en) * | 2005-12-15 | 2007-06-21 | Aerosol Science Laboratories, Inc. | Treatment of active infections and related compositions |
| US20070190163A1 (en) | 2006-01-24 | 2007-08-16 | Malaknov Michael P | Technology for preparation of macromolecular microspheres |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| CN101646775B (zh) | 2006-12-28 | 2016-08-24 | 森托科尔奥索生物科技公司 | 用于产生脱唾液酸化免疫球蛋白的方法和载体 |
| CA2989778C (en) * | 2007-01-19 | 2020-06-30 | Kai Pharmaceuticals, Inc. | Method of modifying peptide compositions |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| EP3058954B1 (en) | 2007-08-27 | 2017-03-01 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
| ES2552858T3 (es) | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| US8187591B2 (en) * | 2007-10-11 | 2012-05-29 | The Regents Of The University Of California | Methods of treating coagulopathy |
| EP2356143A1 (en) * | 2008-11-07 | 2011-08-17 | Anhydro Biologicals Limited | Vaccine compositions |
| JP2010229122A (ja) * | 2009-03-06 | 2010-10-14 | Kumamoto Univ | 抗癌剤、医薬、及び癌疾患の検査薬 |
| CN102448438A (zh) * | 2009-03-26 | 2012-05-09 | 普马特里克斯公司 | 抗流行性感冒调配物及方法 |
| JP2011037765A (ja) * | 2009-08-11 | 2011-02-24 | Kitasato Institute | 新規ペプチド、並びにトリプシン阻害剤、抗インフルエンザウイルス剤、及び抗体 |
| GB0916578D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| US20130164338A1 (en) | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| CA3086367A1 (en) | 2010-09-29 | 2012-04-05 | Pulmatrix Operating Company, Inc. | Monovalent metal cation dry powders for inhalation |
| PT2621488T (pt) | 2010-09-29 | 2019-02-12 | Pulmatrix Operating Co Inc | Pós secos catiónicos |
| EP3494989B1 (en) | 2012-01-26 | 2025-07-16 | Longhorn Vaccines and Diagnostics, LLC | Composite antigenic sequences and vaccines |
| JP2015508780A (ja) | 2012-02-17 | 2015-03-23 | アンサン バイオファーマ，インコーポレイテッド | 免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物 |
| CN104487075A (zh) | 2012-02-29 | 2015-04-01 | 普马特里克斯公司 | 可吸入干粉剂 |
| EP2866792A4 (en) | 2012-06-28 | 2016-08-17 | Ansun Biopharma Inc | MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| WO2014201034A2 (en) | 2013-06-10 | 2014-12-18 | Ansun Biopharma, Inc. | Treatment for polyomavirus infection |
| WO2015184356A1 (en) | 2014-05-30 | 2015-12-03 | Ansun Biopharma, Inc. | Treatment of middle east respiratory syndrome coronavirus |
| WO2016044656A1 (en) * | 2014-09-17 | 2016-03-24 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus d68 |
| KR101629821B1 (ko) | 2015-01-19 | 2016-06-21 | 주식회사 엔터플 | Url 쿠폰을 이용한 디지털 상품 제공 방법 및 장치 |
| WO2016115616A1 (en) * | 2015-01-21 | 2016-07-28 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Inhibition of cellular proteases as treatment for influenza |
| CA2985652C (en) | 2015-05-14 | 2020-03-10 | Gerald W. FISHER | Rapid methods for the extraction of nucleic acids from biological samples |
| US20180271997A1 (en) * | 2016-05-31 | 2018-09-27 | Tianxin Wang | Methods and Reagents to Treat Tumor and Cancer |
| US11459398B2 (en) | 2016-07-01 | 2022-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugates for targeted cell surface editing |
| US20200085849A1 (en) * | 2017-05-18 | 2020-03-19 | Elysium Health, Inc. | Methods and compositions for improving sleep |
| MX2020007024A (es) | 2018-01-03 | 2020-10-28 | Palleon Pharmaceuticals Inc | Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas. |
| GB201814905D0 (en) * | 2018-09-13 | 2018-10-31 | Herwald Heiko | Treatment |
| CA3145772A1 (en) * | 2019-07-03 | 2021-01-07 | Palleon Pharmaceuticals Inc. | Recombinant sialidases and methods of using the same |
| AU2020318955A1 (en) * | 2019-07-23 | 2022-03-03 | Longitude Therapeutics S.R.L. | Platelet-facilitated delivery of therapeutic compounds |
| US12485166B2 (en) | 2020-02-06 | 2025-12-02 | Longhorn Vaccines And Diagnostics, Llc | Vaccines for the treatment and prevention of zoonotic infections |
| GB2615470A (en) | 2020-10-20 | 2023-08-09 | Longhorn Vaccines & Diagnostics Llc | Immunogenic antigens |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3439089A (en) | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| RU2054180C1 (ru) * | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
| US5376633A (en) * | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
| US5985859A (en) * | 1994-04-14 | 1999-11-16 | The University Of Alabama | Methods of inhibiting bacterial sialidase |
| AU5546898A (en) * | 1997-01-14 | 1998-08-07 | Hopital Sainte-Justine | Human lysosomal sialidase and therapeutic uses thereof |
| US6251392B1 (en) | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
| ATE301715T1 (de) * | 1998-10-16 | 2005-08-15 | Fraunhofer Ges Forschung | Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen |
| US6855801B1 (en) | 1999-02-02 | 2005-02-15 | Thomas Jefferson University | Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans |
| US6737511B1 (en) * | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| US20020025320A1 (en) * | 1999-08-20 | 2002-02-28 | Prosper Boyaka | Sialidases as mucosal adjuvants |
| US8084036B2 (en) | 2002-11-22 | 2011-12-27 | Nexbio, Inc. | Broad spectrum anti-viral therapeutics and prophylaxis |
| US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| US20070190163A1 (en) | 2006-01-24 | 2007-08-16 | Malaknov Michael P | Technology for preparation of macromolecular microspheres |
-
2003
- 2003-11-21 US US10/718,986 patent/US8084036B2/en not_active Expired - Lifetime
- 2003-11-21 KR KR1020057009272A patent/KR20050085130A/ko not_active Ceased
- 2003-11-21 AU AU2003294401A patent/AU2003294401C1/en not_active Expired
- 2003-11-21 KR KR1020097016110A patent/KR20090087971A/ko not_active Ceased
- 2003-11-21 CA CA2506526A patent/CA2506526C/en not_active Expired - Lifetime
- 2003-11-21 CN CN200910180019A patent/CN101804200A/zh active Pending
- 2003-11-21 EP EP03789884.8A patent/EP1567185B1/en not_active Expired - Lifetime
- 2003-11-21 WO PCT/US2003/037158 patent/WO2004047735A2/en not_active Ceased
- 2003-11-21 JP JP2005510377A patent/JP5348651B2/ja not_active Expired - Fee Related
- 2003-11-21 CN CN2003801072416A patent/CN1729013B/zh not_active Expired - Lifetime
-
2007
- 2007-08-15 US US11/893,621 patent/US20080075708A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006508193A5 (enExample) | ||
| EP1716232B1 (en) | Acid alpha-glucosidase and fragments thereof | |
| RU2468080C2 (ru) | Новый класс терапевтических белковых молекул | |
| CN1729013B (zh) | 广谱抗病毒化合物、药物制剂及其用途 | |
| EP3981437B1 (en) | Nucleic acid vaccines | |
| US11241486B2 (en) | Treatment of Middle East respiratory syndrome coronavirus | |
| JP2008512117A5 (enExample) | ||
| JP2005537244A (ja) | 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 | |
| JP2017529326A5 (enExample) | ||
| JP2009506033A (ja) | Ｐｌｙ−ｇｂｓ突然変異ライシン | |
| US20200164049A1 (en) | Treatment of human metapneumovirus | |
| US20220111017A1 (en) | Immunomodulatory compositions and methods | |
| US20220233657A1 (en) | Treatment of middle east respiratory syndrome coronavirus | |
| US20180030424A1 (en) | Iduronate-2-sulfatase and use thereof | |
| TW202517789A (zh) | Ｋｌｋ１融合蛋白質的製備方法 | |
| WO2014059403A1 (en) | Chimeric proteins, compositions and methods for restoring cholinesterase function at neuromuscular synapses | |
| CA3096009A1 (en) | Compositions and methods for the prevention and/or treatment of covid-19 | |
| HK1201562B (en) | A novel class of therapeutic protein based molecules | |
| JPWO2022099034A5 (enExample) | ||
| HK1128935A (en) | A novel class of therapeutic protein based molecules | |
| HK1128935B (en) | A novel class of therapeutic protein based molecules |